Main Article Content
This study aimed to review prescribing of bisphosphonates and raloxifene for osteoporosis treatment at the postmenopausal clinic, Health Promoting Hospital, Regional Health Promotion Center 6, Khon Kaen. A review of chart and registry was performed. All medical charts between January 2003 and June 2008 were reviewed (N=103). In this study, indication, dosage, and duration of treatment were examined. Findings showed that all prescribing of alendronate and risedronate were appropriate with recommended indications. The rate of appropriate use of raloxifene was 65% (13 from 20 patients who received raloxifene as the first choice medication). Medications were prescribed as continuous basis. Medications were changed or discontinued only when adverse events occurred or bone mineral density (BMD) T-score decreased from baseline. BMD monitoring for two years after Starting drug treatment was conducted in a small proportion of patients. Three of patients had adverse events in gastrointestinal system including glossitis and abdominal pain from alendronate and risedronate.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
Brecht JG, Kruse HP, Möhrke W, et al. 2004. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 24: 1-10.
Cranney A, Tugwell P, Adachi J, et al. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23: 517–523
Cranney A, Tugwell P, Zytaruk N, et al. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23: 524-528.
Cranney A, Wells G, Willan A, et al. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23: 508-516.
Cueng AM, Feig DS, Kapral M, et al. 2004. The Canadian Task Force on Preventive Health Care. Prevention of osteoporosis and osteoporotic fractures in postemenopausal women: Recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 170: 1665–1667.
Ettinger B, Black DM, Mitlak BH, et al. 1999. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. multiple outcomes of raloxifene evaluation (MORE) investigatiors. JAMA 282: 637–645.
Jarupanich T. 2007. Prevalence and risk factors associated with osteoporosis in women attending menopause clinic at Hat Yai Regional Hospital. J Med Assoc Thai 90: 865-869.
Limpaphayom K, Taechakraichana N, Jaisamrarn U, et al. 2001. Prevalence of osteopenia and osteoporosis in Thai women. Menopause 8: 65-69.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. 2001. Osteoporosis prevention, diagnosis and therapy. JAMA 285: 785-795.
Pocket guide to prevention and treatment of osteoporosis. Washington, D. C.: National Osteoporosis Foundation, 2003. Available at: http://www.nof.org./physguide/inside_cover.htm. Accessed February 3, 2008
Rojanasthien S, Chiewchantanakit S, Vaseenon T. 2005. Diagnosis and treatment of osteoporosis following hip fracture in Chiang Mai University Hospital. J Med Assoc Thai 88 Suppl 5: S65-71.
Taechakraichana N, Angkawanich P, Panyakhamlerd K, et al. 1998. Postmenopausalosteoporosis: What is the real magnitude of the problem? J Med Assoc Thai 81: 397-401.